WO2001034128A3 - Admixture for intravenous administration of linezolid and other antibacterial agents - Google Patents

Admixture for intravenous administration of linezolid and other antibacterial agents Download PDF

Info

Publication number
WO2001034128A3
WO2001034128A3 PCT/US2000/028872 US0028872W WO0134128A3 WO 2001034128 A3 WO2001034128 A3 WO 2001034128A3 US 0028872 W US0028872 W US 0028872W WO 0134128 A3 WO0134128 A3 WO 0134128A3
Authority
WO
WIPO (PCT)
Prior art keywords
linezolid
admixture
intravenous administration
antibacterial agents
administration
Prior art date
Application number
PCT/US2000/028872
Other languages
French (fr)
Other versions
WO2001034128A2 (en
Inventor
Donald H Batts
Original Assignee
Upjohn Co
Donald H Batts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co, Donald H Batts filed Critical Upjohn Co
Priority to AU15721/01A priority Critical patent/AU1572101A/en
Publication of WO2001034128A2 publication Critical patent/WO2001034128A2/en
Publication of WO2001034128A3 publication Critical patent/WO2001034128A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

The present invention is an aqueous admixture of linezolid and an antibacterial agent selected from the group consisting of gentamicin, tobramycin, aztreonam, cefazolin, ceftazidime, piperacillin, ciprofloxacin, ofloxacin, levofloxacin for IV administration.
PCT/US2000/028872 1999-11-08 2000-11-02 Admixture for intravenous administration of linezolid and other antibacterial agents WO2001034128A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU15721/01A AU1572101A (en) 1999-11-08 2000-11-02 Admixture of linezolid and other antibacterial agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16399099P 1999-11-08 1999-11-08
US60/163,990 1999-11-08

Publications (2)

Publication Number Publication Date
WO2001034128A2 WO2001034128A2 (en) 2001-05-17
WO2001034128A3 true WO2001034128A3 (en) 2001-11-22

Family

ID=22592515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/028872 WO2001034128A2 (en) 1999-11-08 2000-11-02 Admixture for intravenous administration of linezolid and other antibacterial agents

Country Status (5)

Country Link
AU (1) AU1572101A (en)
CO (1) CO5251446A1 (en)
EC (1) ECSP003756A (en)
PE (1) PE20011006A1 (en)
WO (1) WO2001034128A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY127336A (en) 2000-03-22 2006-11-30 Upjohn Co Container for linezolid iv solution
PE20020044A1 (en) 2000-06-16 2002-01-30 Upjohn Co THIAZINE OXAZOLIDINONE
WO2004052333A1 (en) * 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
WO2005005424A1 (en) 2003-07-02 2005-01-20 TEVA Gyógyszergyár Részvénytársaság Aztreonam l-lysine and methods for the preparation thereof
BRPI0517200A (en) * 2004-12-17 2008-09-30 Venus Remedies Ltd antibiotic combinations, processes of preparation of a combination of antibiotics and method of treatment
WO2007086014A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising cefpirome, tazobactam and linezolid
WO2007086011A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising cefepime, tazobactam and linezolid
WO2007086012A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation of cefpodoxime, clavulanic acid and linezolid
WO2007086013A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising of ceftazidime, tazobactam and linezolid
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
CN102643251B (en) * 2012-04-17 2016-08-10 四川美大康佳乐药业有限公司 degradation impurity of linezolid and preparation method thereof
CN102973500A (en) * 2012-12-25 2013-03-20 江苏吴中苏药医药开发有限责任公司 Linezolid liquid preparation and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CARON F.: "[Treatment of infections due to glycopeptide-resistant enterococci: Usefu data from animal models]. TRAITEMENT DES INFECTIONS A ENTEROCOQUES RESISTANTS AUX GLYCOPEPTIDES: LECONS TIREES DES MODELES ANIMAUX.", MEDECINE ET MALADIES INFECTIEUSES, (1997) 27/SPEC. ISS. NOV. (946-953)., XP000991559 *
DRESSER L D ET AL: "The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials.", PHARMACOTHERAPY, (1998 MAY-JUN) 18 (3) 456-62. REF: 20, XP000991593 *
FORD, C. W. ET AL: "In vivo efficacy evaluations of U-100592 and U - 100766 new oxazolidinone antibiotics.", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (1995) VOL. 35, NO. 0, PP. 151. MEETING INFO.: 35TH INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY SAN FRANCISCO, CALIFORNIA, USA SEPTEMBER 17-20, 19, XP000991456 *
FORD, CHARLES W. ET AL: "In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections", ANTIMICROB. AGENTS CHEMOTHER. (1996), 40(6), 1508-1513, 1996, XP000654572 *
JACK D.B.: "Doom and gloom over continuing rise in drug-resistant bacteria.", DRUG NEWS AND PERSPECTIVES, (1999) 12/7 (438-442)., XP000991556 *
JUNGBLUTH, G. L. (1) ET AL: "Linezolid and aztreonam: A pharmacokinetic evaluation of intravenous coadministration in healthy volunteers.", CLINICAL INFECTIOUS DISEASES, (1997) VOL. 25, NO. 2, PP. 487. MEETING INFO.: 35TH ANNUAL MEETING OF THE INFECTIOUS DISEASES SOCIETY OF AMERICA, XP000991450 *
MCCANN J.: "ICAAC meeting highlights newest infection fighters", DRUG TOPICS, (18 OCT 1999) 143/20 (48+51)., XP000991459 *
NOSKIN G A ET AL: "Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin.", CLINICAL INFECTIOUS DISEASES, (1999 MAR) 28 (3) 689-90., XP000991539 *
SISSON, THERESA LASHER ET AL: "A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam", J. CLIN. PHARMACOL. (1999), 39(12), 1277-1282, 1999, XP000991041 *
SWEENEY, M. T. (1) ET AL: "In vitro activity of linezolid combined with other antibacteria agents.", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (1999) VOL. 39, PP. 260. CD-ROM. MEETING INFO.: 39TH INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY SAN FRANCISCO, CALIFORNIA, USA SEPTEMBER 26-29, 1, XP000991596 *

Also Published As

Publication number Publication date
PE20011006A1 (en) 2001-09-14
WO2001034128A2 (en) 2001-05-17
CO5251446A1 (en) 2003-02-28
AU1572101A (en) 2001-06-06
ECSP003756A (en) 2002-05-23

Similar Documents

Publication Publication Date Title
WO2001034128A3 (en) Admixture for intravenous administration of linezolid and other antibacterial agents
EE04850B1 (en) Use of pyrimidine derivatives for the preparation of a medicament for the treatment of HIV infection, a compound, a pharmaceutical composition containing it, a process for the preparation of a compound and a composition, and a combination preparation for use in the treatment of HIV infection.
CA2297083A1 (en) Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
MX236443B (en) Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions.
EE200000535A (en) Use of trisubstituted 1,3,5-triazine derivatives for the preparation of a medicament for the treatment of HIV infection, a compound, a pharmaceutical composition containing it, a process for the preparation of a compound and a composition, and
EP1232757A4 (en) Remedies for diseases in association with decrease in bone mass
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
NZ530845A (en) Composition for topical administration
AU5322598A (en) Lozenge for the modified release of active compounds in the gastrointestinal tract
WO1998008505A8 (en) Pharmaceutical compounds
BR9408305A (en) Compound pharmaceutical composition processes for the treatment of AIDS and HIV infection for the preparation of HIV infection and for inhibition of HIV protease and combination of compounds
MXPA01010988A (en) Use of macrolide compounds for the treatment of dry eye.
WO2003082926A3 (en) Antimicrobial polymer conjugates
WO2004007489A3 (en) Antibacterial substituted cyanomethyl (ene) piperidinophenyl oxazolidinones, process or their preparation, and pharmaceutical compositions containing them
WO2003026602A3 (en) Medicine for preventing and treating bromidrosis
CA2380455A1 (en) 9a-azalides with antibacterial activity
WO2000010998A3 (en) Pyridone antibiotic with improved safety profile
MY104109A (en) Antibacterial 9-deoxo-9a-allyl and propargyl-9a-aza-9a-homoerythromycin a derivatives.
Acar A comparison of side effects of levofloxacin to other agents concerning the ecological and microbiological effects on normal human flora
WO2001001975A3 (en) Hypoestoxides, derivatives and agonists thereof for use as antiparasitic agents
HUP0003409A3 (en) Use of macrolide antibiotics for the prepartion of pharmaceutical compositions treating or preventing coccidiosis
EP1143990A3 (en) Pharmaceutical compostions comprising peg-asparaginase for the treatment of hiv infections
MX9700036A (en) Combination therapy for hiv infection.
WO2004007488A3 (en) Antimicrobial oxazolidinones, process of their preparation, and pharmaceutical compositions containing them
WO2001041769A3 (en) Combination of cyamemazine and an atypical neuroleptic

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 521520

Country of ref document: NZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase